Efficiency of Twice Daily Formoterol Versus Once Daily Tiotropium in Patients With GOLD A/B COPD
Status:
Unknown status
Trial end date:
2018-10-31
Target enrollment:
Participant gender:
Summary
Chronic obstructive pulmonary disease (COPD) is a disease state characterized by persistent
airflow limitation and associated with an accelerated decline in lung function, impaired
quality of life, hospitalization, and increased mortality. As a major public health problem,
COPD is predicted to rank as the fifth burden of diseases in the world by 2020. Thus,
prevention of exacerbations is a important goal in the management of COPD. The Global
Initiative for Chronic Obstructive Lung Disease (GOLD) Scientific Committee launched a joint
project in 1998. Its goals were to raise awareness of COPD and to improve prevention and
treatment of COPD patients around the world. In the 2017 GOLD guidelines, inhaled long-acting
bronchodilators, including inhaled long-acting muscarinic antagonists (LAMAs) and inhaled
long-acting beta-agonists (LABAs), are recommended for the management of all stable COPD
patients. However, it is not known whether LABA or LAMA will be more effective for initial
relief of symptoms in patients with GOLD A/B COPD. In this multicenter, randomized study, the
investigators evaluate the efficacy of formoterol(LABA) and tiotropium(LAMA) in the treatment
of patients with GOLD A/B COPD. The primary endpoint is postbronchodilator FEV1, and the
secondary endpoints include the frequency of COPD exacerbation, other lung function
parameters, CCQ score and mMRC/CAT score.